Abstracts tagged "antiphospholipid syndrome"

Abstract Number: 0915 • ACR Convergence 2024
APOH Locus Associated with Higher Anti-Beta-2-Glycoprotein 1 Antibody Levels Paradoxically Protects Against Venous Thromboembolism
Yiming Luo, Lili Liu, Atlas Khan, R. Graham Barr, Elana Bernstein and Krzysztof Kiryluk, Columbia University Irving Medical Center, New York, NY
Background/Purpose: Anti-Beta-2-glycoprotein 1 antibody (anti-B2GP1) is associated with antiphospholipid syndrome (APS), a rare autoimmune disease that causes venous thromboembolism (VTE). APOH, which expresses the B2GP1…
Abstract Number: 0107 • ACR Convergence 2024
Screening for Non-criteria Antiphospholipid Autoantibodies in Patients Younger Than 50 Years Old Admitted for Venous Thromboembolism: A Cross-sectional Study
Yachar DAWUDI¹, Charlotte Gourmelon², Arthur Mageau³, Bénédicte DUMONT⁴, Hélène HELFER⁴, Diane ROUZAUD¹, Thomas Papo³, Isabelle MAHE⁵, Pascale Roland-Nicaise⁶ and Karim Sacré³, ¹Assistance Publique Hôpitaux de Paris, Paris, France, ²Université Paris Saclay, Paris, France, ³Université Paris Cité, Paris, France, ⁴Assistance Publique Hôpitaux de Paris, Colombes, France, ⁵Université Paris Cité, Colombes, France, ⁶Laboratoire d'immunologie, Hôpital Bichat, AP-HP, Paris, France
Background/Purpose: Antiphospholipid syndrome (APS) is an autoimmune disease characterized by the occurrence of thromboses and/or pregnancy morbidity in the presence of persistent antiphospholipid autoantibodies (aPL)…
Abstract Number: 0123 • ACR Convergence 2024
The Impact of Sedentary Behavior and Physical Activity Level on Clinical Parameters and Quality of Life in Patients with Primary Antiphospholipid Syndrome (PAPS)
Carla Silva¹ and Danieli Andrade², ¹University of Sao Paulo, Salvador, Bahia, Brazil, ²University of São Paulo, São Paulo, SP, Brazil
Background/Purpose: PAPS is an autoimmune disease marked by thrombosis, obstetric poor outcomes and antiphospholipid antibodies. Despite treatment, APS is associated with high morbidity and mortality,…
Abstract Number: 1111 • ACR Convergence 2024
Impact of Scleroderma, Antiphospholipid Syndrome, Behçet’s Disease, and Dermatomyositis on Mortality Among Hospitalized Patients with Pulmonary Embolism
Kessiena Aomreore, Lincoln Medical Center, New york, NY
Background/Purpose: Autoimmune diseases are associated with a high prevalence of pulmonary embolism due to the inflammation-induced hyper coagulable state.This study aimed to analyze trends in…
Abstract Number: 0108 • ACR Convergence 2023
Decoding Antiphospholipid Syndrome Laboratory Test Outcomes in a Large Multicenter Electronic Health Record Database
Emily Balczewski, Wenying Liang, Amala Ambati, Yu Zuo, Karandeep Singh and Jason Knight, University of Michigan, Ann Arbor, MI
Background/Purpose: Electronic health record (EHR) data provide an inexpensive, information-rich tool to study rare diseases like antiphospholipid syndrome (APS). Many such studies rely on structured…
Abstract Number: 1605 • ACR Convergence 2023
Complement Activation as a Marker of Thrombosis Risk in Antiphospholipid Antibody Positive Patients: Prospective Results from AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository (“Registry”)
Cecile Yelnik¹, Shruti Chaturvedi², Julien Labreuche¹, Xiang-Zuo Pan³, H Michael Belmont⁴, Kello Nina⁵, Paul R. Fortin⁶, D. Ware Branch⁷, Yu Zuo⁸, Rohan Willis⁹, Robert Brodsky¹⁰, Jane Salmon¹¹, Maria Laura Bertolaccini¹², Hannah Cohen¹³, Michelle Petri¹⁴, Doruk Erkan¹¹ and On Behalf Of APS ACTION¹⁵, ¹University of Lille, Lille, France, ²Johns Hopkins University School of Medicine, Baltimore, MD, ³John Hopkins University, Baltimore, MD, ⁴NYU School of Medicine, New York, NY, ⁵Northwell Health, Brooklyn, NY, ⁶Centre ARThrite - CHU de Québec - Université Laval, Quebec City, QC, Canada, ⁷University of Utah, Salt Lake City, UT, ⁸University of Michigan, Ann Arbor, MI, ⁹University of Texas Medical Branch, Galveston, TX, ¹⁰Johns Hopkins University, Baltimore, MD, ¹¹Hospital for Special Surgery, New York, NY, ¹²King's College London, London, United Kingdom, ¹³University College London Hospitals NHS Foundation Trust, London, United Kingdom, ¹⁴Department of Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine, Timonium, MD, ¹⁵on behalf of APS ACTION, New York, NY
Background/Purpose: Recent studies implicate complement activation in the pathophysiology of antiphospholipid syndrome (APS), especially in patients with severe manifestations, such as catastrophic APS (CAPS). This…
Abstract Number: 0109 • ACR Convergence 2023
Persistent Prothrombotic Activation of Platelet Pannexin 1 Channels in Antiphospholipid Syndrome
Bruna Mazetto, NaveenKumar Somanathapura, Claire Hoy, Christine Rysenga, Srilakshmi Yalavarthi, Cyrus Sarosh, Caroline Ranger, Katarina Kmetova, Jacqueline Madison, Yu Zuo and Jason Knight, University of Michigan, Ann Arbor, MI
Background/Purpose: Inappropriately amplified inflammatory responses are hallmarks of many diseases, with extracellular ATP often playing a central role in the orchestration of inflammation. Regulated cellular…
Abstract Number: 1606 • ACR Convergence 2023
Purinergic Signaling as a Potential Therapeutic Target for APS Thromboinflammation
NaveenKumar K. Somanathapura, Claire Hoy, Srilakshmi Yalavarthi, Cyrus Sarosh, Bruna De Moraes Mazetto Fonseca, Caroline Ranger, Christine Rysenga, Ajay Tambralli, Jacqueline Madison, Yu Zuo and Jason Knight, University of Michigan, Ann Arbor, MI
Background/Purpose: In first responding cells such as neutrophils and platelets, extracellular ATP released from activated or dying cells engages cell-surface receptors to launch proinflammatory and…
Abstract Number: 0110 • ACR Convergence 2023
Neutrophil Extracellular Traps as Mediators of Antiphospholipid Antibody-Induced Trophoblast Dysfunction and Fetal Loss
Christine Rysenga, Srilakshmi Yalavarthi, Wenying Liang, Claire Hoy, Cyrus Sarosh, Richard Lieberman, Yu Zuo and Jason Knight, University of Michigan, Ann Arbor, MI
Background/Purpose: Antiphospholipid antibodies (aPL) induce obstetric complications associated with placental insufficiency by promoting trophoblast dysfunction and inflammation at the maternal-fetal interface. Neutrophils have been found…
Abstract Number: 1607 • ACR Convergence 2023
Autoantibodies to Transcription Factor a Mitochondria Link Mitochondrial Damage and Thrombosis in Systemic Lupus Erythematosus
Eduardo Gomez-Banuelos¹, Alessandra Ida Celia², Maria Isabel Trejo Zambrano³, Merlin Paz³, Erika Darrah³, Daniel Goldman⁴, Michelle Petri⁴ and Felipe Andrade³, ¹The Johns Hopkins University, Baltimore, MD, ²John Hopkins University of Medicine, Rome, Italy, ³Johns Hopkins University, Baltimore, MD, ⁴Department of Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine, Timonium, MD
Background/Purpose: Upon activation with interferon (IFN) and RNP-immune complexes, defective mitophagy in neutrophils results in the release of mtDNA in complex with transcription factor A…
Abstract Number: 0111 • ACR Convergence 2023
Hippo-YAP1-CCN2 Signaling by Microvascular Endothelial Cells Licenses Vascular Smooth Muscle Cell Proliferation in Antiphospholipid Syndrome
Wenying Liang¹, Allison Billi¹, Srilakshmi Yalavarthi¹, Christine Rysenga¹, Claire Hoy¹, Cyrus Sarosh¹, Yu Zuo¹, Eliza Pei-Suen Tsou¹, Jason Knight¹ and Hui Shi², ¹University of Michigan, Ann Arbor, MI, ²Department of Rheumatology and Immunology, Ruijin Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China
Background/Purpose: Some patients with antiphospholipid syndrome (APS) are afflicted by an insidious small-vessel vasculopathy that results in the accrual of organ damage over time. While…
Abstract Number: 1608 • ACR Convergence 2023
Plasma Proteomic Profiling in Antiphospholipid Antibody-positive Patients with Different Clinical Phenotypes: Results from the Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION) Registry
Ayesha Butt¹, Rolando Garcia Milian¹, George Goshua¹, Sean Gu¹, Eugenia Chock², Valentina Restrepo¹, John Hwa¹, Hyung Chun¹, H Michael Belmont³, Kello Nina⁴, D. Ware Branch⁵, Michelle Petri⁶, Jason Knight⁷, Rohan Willis⁸, Maria Laura Bertolaccini⁹, Doruk Erkan¹⁰, Alfred lee¹, Anish Sharda¹ and Alexander Pine¹¹, ¹Yale School of Medicine, New Haven, CT, ²Yale School of Medicine, Greenwich, CT, ³NYU School of Medicine, New York, NY, ⁴Northwell Health, Brooklyn, NY, ⁵University of Utah, Salt Lake City, UT, ⁶Department of Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine, Timonium, MD, ⁷University of Michigan, Ann Arbor, MI, ⁸University of Texas Medical Branch, Galveston, TX, ⁹King's College London, London, United Kingdom, ¹⁰Hospital for Special Surgery, New York, NY, ¹¹VA Connecticut/Yale School of Medicine, West Haven, CT
Background/Purpose: Antiphospholipid syndrome (APS) is an autoimmune disease with thrombotic and obstetric complications arising via a model of immunothrombosis. Patients may present with a spectrum…
Abstract Number: 0096 • ACR Convergence 2023
Performance Assessment of Lupus Anticoagulant Tests Using Taipan and Ecarin Snake Venom Clotting Times: An International Study from Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION) Core Laboratories
Maria Efthymiou¹, Ian Mackie¹, Rohan Willis², Vittorio Pengo³, Danieli Andrade⁴, Elisa Bison³, Olga Amengual⁵, Zurina Romay-Penabad⁶, Yuichiro Fujieda⁵, Maria Laura Bertolaccini⁷, Doruk Erkan⁸, Hannah Cohen⁹ and On Behalf Of APS ACTION¹⁰, ¹University College London, London, United Kingdom, ²University of Texas Medical Branch, Galveston, TX, ³Department of Cardiac-Thoracic-Vascular Sciences and Public Health University of Padova, Padova, Italy, ⁴University of São Paulo, São Paulo, Brazil, ⁵Hokkaido University, Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Sapporo, Japan, ⁶Antiphospholipid Standardization Laboratory, Division of Rheumatology, University of Texas Medical Branch, TX, ⁷King's College London, London, United Kingdom, ⁸Hospital for Special Surgery, New York, NY, ⁹University College London Hospitals NHS Foundation Trust, London, United Kingdom, ¹⁰on behalf of APS ACTION, New York, NY
Background/Purpose: Lupus anticoagulant (LA) test performance is critical for APS diagnosis and management. However, variability remains a challenge in LA testing, particularly in anticoagulated samples,…
Abstract Number: 0112 • ACR Convergence 2023
Molecular Stratification of Antiphospholipid Syndrome Patients Through Integrative Analysis of the Whole-blood RNA Transcriptome
Amala Ambati¹, Feiyang Ma¹, Katarina Kmetova¹, Sherwin Navaz¹, Claire Hoy¹, Cyrus Sarosh¹, Ajay Tambralli¹, Johann E. Gudjonsson¹, J. Michelle Kahlenberg¹, Jacqueline Madison¹, Ali Duarte-Garcia², Jason Knight¹ and Yu Zuo¹, ¹University of Michigan, Ann Arbor, MI, ²Mayo Clinic, Rochester, MN
Background/Purpose: Antiphospholipid syndrome (APS) is an acquired thrombo-inflammatory disease associated with diverse clinical manifestations in the setting of persistent antiphospholipid antibodies (aPL). Early diagnosis and…
Abstract Number: 2324 • ACR Convergence 2023
Leveraging ChatGPT for Real-World Systematic Lupus Erythematosus Data Curation from Electronic Health Records: A Feasibility Study
Lixia Yao, Liwam Gebru, Biruk Aweke, Jay Patel, Ernest Vina, David Fleece and Huanmei Wu, Temple University, Philadelphia, PA
Background/Purpose: Epidemiologists, health services researchers, and health outcome investigators have begun utilizing real-world data (RWD) to gain valuable insights into disease patterns, treatment outcomes, and…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].